What development phase is MOFEZOLAC in?

MOFEZOLAC is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

MOFEZOLAC

FDA-approved approved Small molecule Quality 10/100

At a glance

Generic name	MOFEZOLAC
Drug class	mofezolac
Target	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved
First approval	1994

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MOFEZOLAC CI brief — competitive landscape report
MOFEZOLAC updates RSS · CI watch RSS